Loading, please wait ...

News Analytics

ACADIA Logo Horizontal.
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced top-line results from its Phase 3 ENHANCE study, which evaluated pimavanserin as an adjunctive treatment in adult schizophrenia patients with persistent inadequate response to their current antipsychotic therapy. A total of 396 patients with moderate-to-severe psychotic symptoms were randomized to receive either pimavanserin or placebo added to their current antipsychotic treatment.

The Angle

Subject Matter

  • Healthcare 59.72%
    • Hospitals, doctors and medical care 100.00%
  • Science and technology 40.28%

Emotional Reaction






Dimensions/Depth Chart

If you find a dimension intereseting, we recommend you pick up one or two facts that you find intriguing and place them into your memory. That way you will have 2nd degree information about the topic if it comes up in conversation.

Accordingly, you can do the same with others as well.